New in Brief: Body & Brain | Science News

ADVERTISEMENT

MISSION CRITICAL

Support credible science journalism.

Subscribe to Science News today.


News

New in Brief: Body & Brain

Second-guessing cancer treatments, a boyish side to soy and more in this week's news

By
10:59am, August 11, 2011

Two-drug therapy for lung cancer
Patients age 70 or older with lung cancer should get two drugs rather than the currently recommended single-drug therapy, scientists in France report online August 9 in the Lancet. The researchers randomly assigned 448 lung cancer patients, median age 77, to get either two standard chemotherapies or one. The double-treatment group had a median survival time of 10.3 months, and 45 percent lived longer than one year. The single-drug group survived a median of 6.2 months and only 25 percent survived a year. Despite observing more side effects in the double-therapy patients, the researchers argue that the longer survival times suggest that current treatment guidelines be reconsidered. —Nathan Seppa

This article is available only to subscribing members. Join the Society today or Log in.

Get Science News headlines by e-mail.

More from Science News

From the Nature Index Paid Content